The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index.
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
Open accessAbstract
BACKGROUND: Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor that carries a 5-y survival rate of 5%. Attempts at eliciting a clinically relevant anti-GBM immune response in brain tumor patients have met with limited success, which is due to brain immune privilege, tumor immune evasion, and a paucity of dendritic cells (DCs) within the central nervous system. Herein we uncovered a novel pathway for the activation of an effective anti-GBM immune response mediated by high-mobility-group box 1 (HMGB1), an alarmin protein released from dying tumor cells, which acts as an endogenous ligand for Toll-like receptor 2 (TLR2) signaling on bone marrow-derived GBM-infiltrating DCs. METHODS AND FINDINGS: Using a combined immunotherapy/conditional cytotoxic approach that utilizes adenoviral vectors (Ad) expressing Fms-like tyrosine kinase 3 ligand (Flt3L) and thymidine kinase (TK) delivered into the tumor mass, we demonstrated that CD4(+) and CD8(+) T cells were required for tumor regression and immunological memory. Increased numbers of bone marrow-derived, tumor-infiltrating myeloid DCs (mDCs) were observed in response to the therapy. Infiltration of mDCs into the GBM, clonal expansion of antitumor T cells, and induction of an effective anti-GBM immune response were TLR2 dependent. We then proceeded to identify the endogenous ligand responsible for TLR2 signaling on tumor-infiltrating mDCs. We demonstrated that HMGB1 was released from dying tumor cells, in response to Ad-TK (+ gancyclovir [GCV]) treatment. Increased levels of HMGB1 were also detected in the serum of tumor-bearing Ad-Flt3L/Ad-TK (+GCV)-treated mice. Specific activation of TLR2 signaling was induced by supernatants from Ad-TK (+GCV)-treated GBM cells; this activation was blocked by glycyrrhizin (a specific HMGB1 inhibitor) or with antibodies to HMGB1. HMGB1 was also released from melanoma, small cell lung carcinoma, and glioma cells treated with radiation or temozolomide. Administration of either glycyrrhizin or anti-HMGB1 immunoglobulins to tumor-bearing Ad-Flt3L and Ad-TK treated mice, abolished therapeutic efficacy, highlighting the critical role played by HMGB1-mediated TLR2 signaling to elicit tumor regression. Therapeutic efficacy of Ad-Flt3L and Ad-TK (+GCV) treatment was demonstrated in a second glioma model and in an intracranial melanoma model with concomitant increases in the levels of circulating HMGB1. CONCLUSIONS: Our data provide evidence for the molecular and cellular mechanisms that support the rationale for the clinical implementation of antibrain cancer immunotherapies in combination with tumor killing approaches in order to elicit effective antitumor immune responses, and thus, will impact clinical neuro-oncology practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. (1989) · Technometrics · doi:10.1080/00401706.1989.10488618 · Cited by 99,167
Statistical power analysis for the behavioral sciences
(1990) · Computers, Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,269
Pathogen Recognition and Innate Immunity
Akira, S., Uematsu, S., & Takeuchi, O. (2006) · Cell · doi:10.1016/j.cell.2006.02.015 · Cited by 11,952
The Danger Model: A Renewed Sense of Self
Matzinger, P. (2002) · Science · doi:10.1126/science.1071059 · Cited by 4,205
Toll-like receptor control of the adaptive immune responses
Iwasaki, A., & Medzhitov, R. (2004) · Nature Immunology · doi:10.1038/ni1112 · Cited by 4,193
Inaba, K., Inaba, M., Romani, N., Aya, H., Deguchi, M., Ikehara, S., Muramatsu, S., & Steinman, R. M. (1992) · The Journal of experimental medicine · doi:10.1084/jem.176.6.1693 · Cited by 3,738
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385
Takeuchi, O., Hoshino, K., Kawai, T., Sanjo, H., Takada, H., Ogawa, T., Takeda, K., & Akira, S. (1999) · Immunity · doi:10.1016/s1074-7613(00)80119-3 · Cited by 3,362
Yang, Y., Li, S., Yang, Q., Shi, Y., Zheng, M., Liu, Y., Chen, F., Song, G., Xu, H., Wan, T., et al. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358696 · Cited by 3,253
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 3×
“16 tumor regression induced by standard chemotherapeutic agents by activating TLR4 [9].”
BackgroundNF-κB in cancer: from innocent bystander to major culprit
Karin, M., Cao, Y., Greten, F. R., & Li, Z.-W. (2002) · Nature Reviews Cancer · doi:10.1038/nrc780 · Cited by 2,478
Ohashi, K., Burkart, V., Flohé, S., & Kolb, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.2.558 · Cited by 1,606
Natural adjuvants: Endogenous activators of dendritic cells
Gallucci, S., Lolkema, M., & Matzinger, P. (1999) · Nature Medicine · doi:10.1038/15200 · Cited by 1,602
MyD88 Is an Adaptor Protein in the hToll/IL-1 Receptor Family Signaling Pathways
Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., & Janeway, C. A. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80136-7 · Cited by 1,575
Park, J. S., Svetkauskaite, D., He, Q., Kim, J.-Y., Strassheim, D., Ishizaka, A., & Abraham, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306793200 · Cited by 1,562
Perivascular microglial cells of the CNS are bone marrow-derived and present antigen in vivo
Hickey, W. F., & Kimura, H. (1988) · Science · doi:10.1126/science.3276004 · Cited by 1,466
Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases
Taguchi, A., Blood, D. C., del Toro, G., Canet, A., Lee, D. C., Qu, W., Tanji, N., Lu, Y., Lalla, E., Fu, C., et al. (2000) · Nature · doi:10.1038/35012626 · Cited by 1,217
Primary brain tumours in adults
Ricard, D., Idbaih, A., Ducray, F., Lahutte, M., Hoang-Xuan, K., & Delattre, J.-Y. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61346-9 · Cited by 1,201
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Toll-like receptors in systemic autoimmune disease
Marshak-Rothstein, A. (2006) · Nature Reviews Immunology · doi:10.1038/nri1957 · Cited by 1,116
The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemia-reperfusion
Tsung, A., Sahai, R., Tanaka, H., Nakao, A., Fink, M. P., Lotze, M. T., Yang, H., Li, J., Tracey, K. J., Geller, D. A., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042614 · Cited by 1,113
HSP70 as Endogenous Stimulus of the Toll/Interleukin-1 Receptor Signal Pathway
Vabulas, R. M., Ahmad-Nejad, P., Ghose, S., Kirschning, C. J., Issels, R. D., & Wagner, H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111204200 · Cited by 948
CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and Calreticulin
Basu, S., Binder, R. J., Ramalingam, T., & Srivastava, P. K. (2001) · Immunity · doi:10.1016/s1074-7613(01)00111-x · Cited by 900
HMGB1 SIGNALS THROUGH TOLL-LIKE RECEPTOR (TLR) 4 AND TLR2
Yu, M., Wang, H., Ding, A., Golenbock, D. T., Latz, E., Czura, C. J., Fenton, M. J., Tracey, K. J., & Yang, H. (2006) · Shock · doi:10.1097/01.shk.0000225404.51320.82 · Cited by 832 · cited 1×
“HMGB1 can also activate TLR2 in addition to TLR4 and differential TLR activation appears to depend on the particular tumor model used [58].”
BackgroundToll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages
Underhill, D. M., Ozinsky, A., Smith, K. D., & Aderem, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.25.14459 · Cited by 827
Current Protocols in Neuroscience
(2018) · Current Protocols in Neuroscience · doi:10.1002/(issn)1934-8576 · Cited by 767
Primary brain tumours in adults
Behin, A., Hoang-Xuan, K., Carpentier, A. F., & Delattre, J.-Y. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12328-8 · Cited by 754
Human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide
Kirschning, C. J., Wesche, H., Merrill Ayres, T., & Rothe, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.11.2091 · Cited by 753
Hyaluronan Fragments Act as an Endogenous Danger Signal by Engaging TLR2
Scheibner, K. A., Lutz, M. A., Boodoo, S., Fenton, M. J., Powell, J. D., & Horton, M. R. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.2.1272 · Cited by 708 · cited 1×
“For example, TLR2 signaling can be stimulated in response to host-derived molecules including gp96 [57,68], HMGB1 [69], low molecular weight hyaluronan fragments [55], soluble CD14 [29,70], and possibly larger hydrophobic molecular complexes (Hyppo’s) [71].”
BackgroundThe CNS role of Toll-like receptor 4 in innate neuroimmunity and painful neuropathy
Tanga, F. Y., Nutile-McMenemy, N., & DeLeo, J. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501634102 · Cited by 634
Glycyrrhizin Binds to High-Mobility Group Box 1 Protein and Inhibits Its Cytokine Activities
Mollica, L., De Marchis, F., Spitaleri, A., Dallacosta, C., Pennacchini, D., Zamai, M., Agresti, A., Trisciuoglio, L., Musco, G., & Bianchi, M. E. (2007) · Chemistry & Biology · doi:10.1016/j.chembiol.2007.03.007 · Cited by 612
Modulation of atherosclerosis in mice by Toll-like receptor 2
Mullick, A. E. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25482 · Cited by 549
Vabulas, R. M., Braedel, S., Hilf, N., Singh-Jasuja, H., Herter, S., Ahmad-Nejad, P., Kirschning, C. J., da Costa, C., Rammensee, H.-G., Wagner, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m200425200 · Cited by 488
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
Baccala, R., Hoebe, K., Kono, D. H., Beutler, B., & Theofilopoulos, A. N. (2007) · Nature Medicine · doi:10.1038/nm1590 · Cited by 473
Akashi, S., Shimazu, R., Ogata, H., Nagai, Y., Takeda, K., Kimoto, M., & Miyake, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.7.3471 · Cited by 460
Observation of Antigen-Dependent CD8+ T-Cell/ Dendritic Cell Interactions in Vivo
Schaefer, B. C., Schaefer, M. L., Kappler, J. W., Marrack, P., & Kedl, R. M. (2001) · Cellular Immunology · doi:10.1006/cimm.2001.1895 · Cited by 393
Hou, B., Reizis, B., & DeFranco, A. L. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.016 · Cited by 363
Candolfi, M., Curtin, J. F., Nichols, W. S., Muhammad, A. G., King, G. D., Pluhar, G. E., McNiel, E. A., Ohlfest, J. R., Freese, A. B., Moore, P. F., et al. (2007) · Journal of Neuro-Oncology · doi:10.1007/s11060-007-9400-9 · Cited by 351
Self-citationKokkola, R., Li, J., Sundberg, E., Aveberger, A. ‐., Palmblad, K., Yang, H., Tracey, K. J., Andersson, U., & Harris, H. E. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11161 · Cited by 325
Dewey, R. A., Morrissey, G., Cowsill, C. M., Stone, D., Bolognani, F., Dodd, N. J. F., Southgate, T. D., Klatzmann, D., Lassmann, H., Castro, M. G., et al. (1999) · Nature Medicine · doi:10.1038/15207 · Cited by 311
Self-citationIKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα
Maeda, S., Chang, L., Li, Z.-W., Luo, J.-L., Leffert, H., & Karin, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00301-7 · Cited by 286
The secretion of HMGB1 is required for the migration of maturing dendritic cells
Dumitriu, I. E., Bianchi, M. E., Bacci, M., Manfredi, A. A., & Rovere-Querini, P. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306171 · Cited by 247
TLR2 has a detrimental role in mouse transient focal cerebral ischemia
Ziegler, G., Harhausen, D., Schepers, C., Hoffmann, O., Röhr, C., Prinz, V., König, J., Lehrach, H., Nietfeld, W., & Trendelenburg, G. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.05.157 · Cited by 237
Yang, R., Harada, T., Mollen, K. P., Prince, J. M., Levy, R. M., Englert, J. A., Gallowitsch-Puerta, M., Yang, L., Yang, H., Tracey, K. J., et al. (2006) · Molecular Medicine · doi:10.2119/2006-00010.yang · Cited by 224
Tumor immunoediting and immunosculpting pathways to cancer progression
Reiman, J. M., Kmieciak, M., Manjili, M. H., & Knutson, K. L. (2007) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2007.06.009 · Cited by 199
Toll-like Receptor 2 Senses β-Cell Death and Contributes to the Initiation of Autoimmune Diabetes
Kim, H. S., Han, M. S., Chung, K. W., Kim, S., Kim, E., Kim, M. J., Jang, E., Lee, H. A., Youn, J., Akira, S., et al. (2007) · Immunity · doi:10.1016/j.immuni.2007.06.010 · Cited by 195
Toll-Like Receptor 2 Signaling in Response to Brain Injury: An Innate Bridge to Neuroinflammation
Babcock, A. A., Wirenfeldt, M., Holm, T., Nielsen, H. H., Dissing-Olesen, L., Toft-Hansen, H., Millward, J. M., Landmann, R., Rivest, S., Finsen, B., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.4937-05.2006 · Cited by 185
Natsume, A., Ishii, D., Wakabayashi, T., Tsuno, T., Hatano, H., Mizuno, M., & Yoshida, J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0036 · Cited by 171
Gene Therapy for Malignant Glioma: Current Clinical Status
Pulkkanen, K. J., & Yla-Herttuala, S. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.07.357 · Cited by 161
Sequence Variants in Toll-Like Receptor Gene Cluster (TLR6-TLR1-TLR10) and Prostate Cancer Risk
Sun, J., Wiklund, F., Zheng, S. L., Chang, B., Balter, K., Li, L., Johansson, J.-E., Li, G., Adami, H.-O., Liu, W., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji070 · Cited by 161
Inflammation and Cancer: A Double-Edged Sword
Hagemann, T., Balkwill, F. R., & Lawrence, T. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.005 · Cited by 157
Li, Y., Du, H., Qin, Y., Roberts, J., Cummings, O. W., & Yan, C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0647 · Cited by 146
Nieters, A., Beckmann, L., Deeg, E., & Becker, N. (2006) · Genes and Immunity · doi:10.1038/sj.gene.6364337 · Cited by 143
Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice
Sitia, G., Iannacone, M., Müller, S., Bianchi, M. E., & Guidotti, L. G. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306173 · Cited by 139
Treg Depletion Inhibits Efficacy of Cancer Immunotherapy: Implications for Clinical Trials
Curtin, J. F., Candolfi, M., Fakhouri, T. M., Liu, C., Alden, A., Edwards, M., Lowenstein, P. R., & Castro, M. G. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001983 · Cited by 132
Self-citationGhitza, U. E., Fabbricatore, A. T., Prokopenko, V. F., Pawlak, A. P., & West, M. O. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-19-07239.2003 · Cited by 132
Tahara, T., Arisawa, T., Wang, F., Shibata, T., Nakamura, M., Sakata, M., Hirata, I., & Nakano, H. (2007) · Cancer Science · doi:10.1111/j.1349-7006.2007.00590.x · Cited by 128
Ali, S., King, G. D., Curtin, J. F., Candolfi, M., Xiong, W., Liu, C., Puntel, M., Cheng, Q., Prìeto, J., Ribas, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3434 · Cited by 126
Self-citationHeimberger, A. B., Sun, W., Hussain, S. F., Dey, M., Crutcher, L. M., Aldape, K., Gilbert, M. R., Hassenbusch, S. J., Sawaya, R. A., Schmittling, B., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-046 · Cited by 126
Molenkamp, B. G., Sluijter, B. J. R., van Leeuwen, P. A. M., Santegoets, S. J. A. M., Meijer, S., Wijnands, P. G. J. T. B., Haanen, J. B. A. G., van den Eertwegh, A. J. M., Scheper, R. J., & de Gruijl, T. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4711 · Cited by 125
Lowenstein, P. R. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02063-4 · Cited by 121
Self-citationMorse, D. T. (1999) · Educational and Psychological Measurement · doi:10.1177/00131649921969901 · Cited by 121
Fujita, M., Zhu, X., Sasaki, K., Ueda, R., Low, K. L., Pollack, I. F., & Okada, H. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.4.2089 · Cited by 108
Atreya, R. N., & Neurath, M. (2008) · Current Drug Targets · doi:10.2174/138945008784221116 · Cited by 107
Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance
Ehlers, M., & Ravetch, J. V. (2007) · Trends in Immunology · doi:10.1016/j.it.2006.12.006 · Cited by 107
Inflammation and cancer: The oncogene-driven connection
Borrello, M. G., Degl’Innocenti, D., & Pierotti, M. A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.060 · Cited by 106
Immunotherapy of malignant brain tumors
Mitchell, D. A., Fecci, P. E., & Sampson, J. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00603.x · Cited by 104
TLR ligands differentially affect uptake and presentation of cellular antigens
Weck, M. M., Grünebach, F., Werth, D., Sinzger, C., Bringmann, A., & Brossart, P. (2007) · Blood · doi:10.1182/blood-2006-04-015719 · Cited by 103
Microsatelite GT polymorphism in the toll‐like receptor 2 is associated with colorectal cancer
Jelavić, T. B., Barišić, M., Hofman, I. D., Perica, V. B., Vrdoljak, E., Peruzović, M., Hozo, I., Puljiz, Ž., & Terzić, J. (2006) · Clinical Genetics · doi:10.1111/j.1399-0004.2006.00651.x · Cited by 100
Naiki, Y., Michelsen, K. S., Schröder, N. W. J., Alsabeh, R., Slepenkin, A. V., Zhang, W., Chen, S., Wei, B., Bulut, Y., Wong, M. H., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m503225200 · Cited by 98
Self-citationWang, H. Y., Fu, T., Wang, G., Zeng, G., Perry-Lalley, D. M., Yang, J. C.-H., Restifo, N. P., Hwu, P., & Wang, R. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15399 · Cited by 93
Fms-Like Tyrosine Kinase 3 Ligand Recruits Plasmacytoid Dendritic Cells to the Brain
Curtin, J. F., King, G. D., Barcia, C., Liu, C., Hubert, F., Guillonneau, C., Josien, R., Anegón, I., Lowenstein, P. R., & Castro, M. G. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.6.3566 · Cited by 92
Self-citationAli, S., Curtin, J. F., Zirger, J. M., Xiong, W., King, G. D., Barcia, C., Liu, C., Puntel, M., Goverdhana, S., Lowenstein, P. R., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.025 · Cited by 85
Self-citationCpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Haining, W. N., DAVIES, J. K., Kanzler, H., Drury, L., Brenn, T., Evans, J., Angelosanto, J., Rivoli, S., Russell, K. E. R., George, S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0526 · Cited by 76
Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model
King, G. D., Muhammad, A. K. M. G., Curtin, J. F., Barcia, C., Puntel, M., Liu, C., Honig, S. B., Candolfi, M., Mondkar, S., Lowenstein, P. R., et al. (2007) · Neuro-Oncology · doi:10.1215/15228517-2007-045 · Cited by 76
Self-citationRadioresistance is associated to increased Hsp70 content in human glioblastoma cell lines
da Rocha, A. B., Regner, A., Grivicich, I., Schunemann, D. P., Diel, C. L., Kovaleski, G., de Farias, C. B., Mondadori, E., Almeida, L., Filho, A. B., et al. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.777 · Cited by 65
Gene Transfer into Neural Cells In Vitro Using Adenoviral Vectors
Southgate, T. D., Kingston, P. A., & Castro, M. G. (2000) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0423s13 · Cited by 64
Self-citationSun, J., Wiklund, F. E., Hsu, F., Bälter, K. A., Zheng, S., Johansson, J., Chang, B., Liu, W., Li, T., Turner, A. R., et al. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0645 · Cited by 59
Ghitza, U. E., Fabbricatore, A. T., Prokopenko, V. F., & West, M. O. (2004) · Journal of Neurophysiology · doi:10.1152/jn.00268.2004 · Cited by 55
Combining Cytotoxic and Immune-Mediated Gene Therapy to Treat Brain Tumors
Curtin, J. F., King, G. D., Candolfi, M., Greeno, R., Kroeger, K. M., Lowenstein, P. R., & Castro, M. G. (2005) · Current Topics in Medicinal Chemistry · doi:10.2174/156802605774370856 · Cited by 53
Self-citationGene Transfer into Neural Cells In Vitro Using Adenoviral Vectors
Southgate, T. D., Kroeger, K. M., Liu, C., Lowenstein, P. R., & Castro, M. G. (2008) · Current Protocols in Neuroscience · doi:10.1002/0471142301.ns0423s45 · Cited by 37
Self-citationMINSIZE: A Computer Program for Obtaining Minimum Sample Size as an Indicator of Effect Size
Morse, D. T. (1998) · Educational and Psychological Measurement · doi:10.1177/0013164498058001012 · Cited by 15
Cited by
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
The Microenvironmental Landscape of Brain Tumors
Quail, D. F., & Joyce, J. A. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.009 · Cited by 1,862
TIM3 comes of age as an inhibitory receptor
Wolf, Y., Anderson, A. C., & Kuchroo, V. K. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0224-6 · Cited by 959
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citation
Metadata
- Authors
- Curtin, J. F., Liu, N., Candolfi, M., Xiong, W., Assi, H., Yagiz, K., Edwards, M. R., Michelsen, K. S., Kroeger, K. M., Liu, C., Muhammad, A. K. M. G., Clark, M. C., Arditi, M., Comin-Anduix, B., Ribas, A., Lowenstein, P. R., & Castro, M. G.
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-01-13
- Volume
- 6
- Issue
- 1
- Pages
- e1000010
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2116126240
- Cited by
- 364
- References
- 82
- FWCI
- 11.58
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.